Premium
Long‐term results of disodium etidronate treatment in pulmonary alveolar microlithiasis
Author(s) -
Ozcelik Ugur,
Yalcin Ebru,
Arıyurek Macit,
Ersoz Deniz Dogru,
Cinel Guzin,
Gulhan Bora,
Kiper Nural
Publication year - 2010
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.21209
Subject(s) - medicine , lung disease , respiratory disease , lung , pathology
Pulmonary alveolar microlithiasis (PAM) is a rare disease with alveolar microliths mainly composed of calcium phosphate. The gene responsible for the disease is SLC34A2 , which encodes a type‐IIb sodium phosphate cotransporter, has been described recently. Treatment of this disease is not clearly defined. Disodium etidronate is a member of bisphonates and it has been administered in these patients due to its inhibitory effect on the precipitation of hydroxyapatite microcrystals. Here, clinical and radiological improvement of two patients with PAM who were treated with disodium etidronate for 9 and 11 years, respectively, are presented. The pathogenetic mechanism of this treatment on the genetic basis of disease is discussed. Pediatr Pulmonol. 2010; 45:514–517. © 2010 Wiley‐Liss, Inc.